Ardelyx Inc. (NASDAQ: ARDX) stock gained by 1.03% in the current market trading session. Ardelyx is dedicated to discovering, developing, and promoting novel first-in-class medications that will improve the lives of people suffering from kidney and cardiorenal illnesses.
>> 7 Top Picks for the Post-Pandemic Economy <<
ARDX stock’ Current Development
The results of Ardelyx’s 52-week Phase 3 PHREEDOM trial have been published in Kidney360, the journal of the American Society of Nephrology.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Mike Raab, president, and chief executive officer of Artily said that the PHREEDOM experiment, a 52-week randomized Phase 3 trial evaluating tenapanor monotherapy, was the third of three Phase 3 trials they performed in the complete investigation of tenapanor for serum phosphorus management in patients on dialysis with chronic kidney disease. The PHREEDOM results show that tenapanor can reduce phosphorus levels significantly while maintaining a level of long-term safety that is comparable to active control.
This research, combined with results from their AMPLIFY trial, demonstrates the critical role that tenapanor, with its new blocking action, can serve in the treatment of hyperphosphatemia in patients on dialysis with serious kidney disease.
Arnold Silva, director of Clinical Research at Boise Kidney and Hypertension Institute, further stated,
As a researcher in this clinical research and an author on this paper, he had the chance to see the influence of tenapanor on serum phosphorus management firsthand and in bulk. He feels that this innovative mechanism therapy will be critical in improving the treatment of hyperphosphatemia in the dialysis patients with CKD. Therapy options have been restricted in this area, and despite treatment response with currently available medications, a significant proportion of patients have phosphorus levels above goal values. Furthermore, whether taken alone or in conjunction with phosphate binders, a one pill twice daily therapy that limits phosphorus absorption has the potential to lessen treatment burden, which will be a substantial advantage to patients.
